Inflammatory Activation Of Microglia Research Articles

Microglia in Alzheimer's disease.

Microglia are brain-resident myeloid cells that mediate key functions to support the CNS. Microglia express a wide range of receptors that act as molecular sensors, which recognize exogenous or endogenous CNS insults and initiate an immune response. In addition to their classical immune cell function, microglia act as guardians of the brain by promoting phagocytic clearance and providing trophic support to ensure tissue repair and maintain cerebral homeostasis. Conditions associated with loss of homeostasis or tissue changes induce several dynamic microglial processes, including changes of cellular morphology, surface phenotype, secretory mediators, and proliferative responses (referred to as an "activated state"). Activated microglia represent a common pathological feature of several neurodegenerative diseases, including Alzheimer's disease (AD). Cumulative evidence suggests that microglial inflammatory activity in AD is increased while microglial-mediated clearance mechanisms are compromised. Microglia are perpetually engaged in a mutual interaction with the surrounding environment in CNS; thus, diverse microglial reactions at different disease stages may open new avenues for therapeutic intervention and modification of inflammatory activities. In this Review, the role of microglia in the pathogenesis of AD and the modulation of microglia activity as a therapeutic modality will be discussed.

Microglial Inflammatory Signaling Orchestrates the Hypothalamic Immune Response to Dietary Excess and Mediates Obesity Susceptibility

Dietary excess triggers accumulation of pro-inflammatory microglia in the mediobasal hypothalamus (MBH), but the components of this microgliosis andits metabolic consequences remain uncertain. Here, we show that microglial inflammatory signaling determines the immunologic response of the MBH todietary excess and regulates hypothalamic controlof energy homeostasis in mice. Either pharmacologically depleting microglia or selectively restraining microglial NF-κB-dependent signaling sharply reduced microgliosis, an effect that includes prevention of MBH entry by bone-marrow-derived myeloid cells, and greatly limited diet-induced hyperphagia and weight gain. Conversely, forcing microglial activation through cell-specific deletion of the negative NF-κB regulator A20 induced spontaneous MBH microgliosis and cellular infiltration, reduced energy expenditure, and increased both food intakeand weight gain even in absence of adietary challenge. Thus, microglial inflammatory activation,stimulated by dietary excess, orchestrates a multicellular hypothalamic response that mediates obesity susceptibility, providing a mechanistic rationale for non-neuronal approaches to treat metabolic diseases.

Neuroprotective effects of lutein in neonatal hypoxic‐ischemic brain injury

BackgroundHypoxic‐ischemic (HI) brain injury is a leading cause of neonatal mortality and, in survivors, of severe neurological disability and it is a major source of developmental and cognitive impairments in children and adults. In HI, injury pathways include excitotoxicity, inflammation, and oxidative stress. The carotenoid lutein (and its isomer zeaxanthin) are selectively taken up and accumulated in the brain. Based on the lutein effects in improving later life cognition, we postulated lutein may have neuroprotective effects in HI.MethodsWe used a validated neonatal rat model of HI brain injury induced by unilateral carotid artery ligation (ischemia) on postnatal day 7 (P7) and subsequent exposure to 8% oxygen (hypoxia) for 2.5 h. Dams were fed a lutein‐rich or control chow diet throughout pregnancy and lactation. From P7 (HI) to P10 (sacrifice), nursing pups also received lutein or vehicle by intra‐peritoneal injection. Brain sections were examined with H&E, Nissl, and immunohistochemical staining and apoptotic assays. Protein expression (e.g., HIF‐1α, nNOS) was evaluated by western blot. RT‐qPCR expression arrays were used to evaluate changes in expression of targeted genes involved in hypoxic, apoptotic, and neuroinflammatory pathways.ResultsLutein supplementation resulted in lutein accumulation in milk and neonatal brain tissues. Lutein treatment, in this model, reduced histological brain injury scores and suppressed: (a) RNA and protein expression of key neuroinflammatory mediators, (b) expression of hypoxia‐inducible proteins (including HIF‐1α), and (c) microglial (inflammatory) activation in several brain regions particularly susceptible to HI injury. Additionally, lutein exerted anti‐apoptotic effects including altered expression of several apoptosis‐related genes: BIK, Birc5, Bnic2, and Casp2–6.ConclusionThese results demonstrate: (1) there is maternal/fetal transfer and uptake of dietary lutein into milk and brain in the rat; (2) this rodent model is informative for testing the effects of lutein on HI brain injury and neurodevelopment; and (3) pre‐ and peri‐injury lutein administration suppresses multiple deleterious response pathways in HI. These findings suggest lutein supplementation is a promising preventive and therapeutic strategy for limiting pathological consequences of HI brain injury. This model including manipulation of lutein intake is applicable to other brain disorders including traumatic brain injury, intracranial hemorrhage, and stroke.Support or Funding InformationSeed grant from Texas Tech University Health Sciences Center El Paso

Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-κB

The triggering receptor expressed on myeloid cells (TREM) family of proteins are cell surface receptors with important roles in regulation of myeloid cell inflammatory activity. In the central nervous system, TREM2 is implicated in further roles in microglial homeostasis, neuroinflammation and neurodegeneration. Different TREM receptors appear to have contrasting roles in controlling myeloid immune activity therefore the relative and co-ordinated regulation of their expression is important to understand but is currently poorly understood. We sought to determine how microglial TREM expression is affected under neuroinflammatory conditions in vitro and in vivo. Our data show that microglial Trem1 and Trem2 gene expression are regulated in an opposing manner by lipopolysaccharide (LPS) in vitro in both adult murine and human microglia. LPS caused a significant induction of Trem1 and a contrasting suppression of Trem2 expression. We also observed similar divergent Trem1 and Trem2 responses in vivo in response to acute brain inflammation and acute cerebral ischaemia. Our data show that inhibition of NF-κB activation prevents the LPS-induced alterations in both Trem1 and Trem2 expression in vitro indicating NF-κB as a common signaling intermediate controlling these divergent responses. Distinct patterns of microglial Trem1 induction and Trem2 suppression to different Toll-like receptor (TLR) ligands were also evident, notably with Trem1 induction restricted to those ligands activating TLRs signaling via TRIF. Our data show co-ordinated but divergent regulation of microglial TREM receptor expression with a central role for NF-κB. Neuroinflammatory conditions that alter the balance in TREM expression could therefore be an important influence on microglial inflammatory and homeostatic activity with implications for neuroinflammatory and neurodegenerative disease.

Abstract WMP45: Targeted Inhibition of the Alternative Complement Pathway Enhances Rehabilitation-Induced Cognitive and Motor Recovery in a Murine Model of Chronic Stroke

Introduction: Activation of inflammatory cascades after stroke exacerbate acute injury and limit response to rehabilitation (rehab). The complement (C) system is a prominent component of inflammatory injury after stroke, but can also contribute to neuroprotective recovery processes. We investigated the neuroprotective effects of CR2fH, a site-targeted C inhibitor that specifically inhibits the alternative pathway and prevents amplification of the C cascade. We assessed how CR2fH affects chronic outcomes, and how acute C inhibition impacts the response to rehab therapy. Methods: Mice were subjected to 1hr middle cerebral artery occlusion and 15 days of reperfusion. Mice were treated with CR2fH or vehicle and then randomized to normal housing or an enriched environment (EE) to model cognitive and motor rehab. Animals were assessed for infarct volume using MRI at days 4 and 14 after injury, and for their performance on several motor and cognitive tasks. Expression of inflammatory markers in the brain was assessed using high throughput Nanostring analysis and immunostaining. Results: Compared to vehicle or EE only, treatment with CR2fH 90 mins after cerebral ischemia significantly reduced infarct volume and improved motor and cognitive performance up to 15 days, as assessed with mNSS scores, corner task, locomotor activity, pasta handling, and passive avoidance tasks (p’s<0.01). Less prominent, although still significant improvement was also achieved when CR2fH was administered 6 or 12 hrs. after ischemia (p’s<0.05). EE alone did not significantly reduce infarct volume or improve performance on motor tasks, but resulted in a significant improvement in cognitive performance compared to vehicle (p’s<0.05). A combination of EE and CR2fH therapy resulted in a significant potentiation of cognitive and motor recovery compared to either single intervention (p’s<0.05). CR2fH related behavioral improvements correlated with reduction in C deposition and inflammatory microglial activation during recovery. Conclusions: Since a humanized version of CR2fH, TT30, was shown to be safe, tolerated and nonimmunogenic in humans, targeted inhibition of alternative C pathway is a candidate therapy to promote recovery and potentiate response to rehab after stroke.

Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation.

CSP-1103 (formerly CHF5074) has been shown to reverse memory impairment and reduce amyloid plaque as well as inflammatory microglia activation in preclinical models of Alzheimer’s disease. Moreover, it was found to improve cognition and reduce brain inflammation in patients with mild cognitive impairment. Recent evidence suggests that CSP-1103 acts through a single molecular target, the amyloid precursor protein intracellular domain (AICD), a transcriptional regulator implicated in inflammation and apoptosis. We here tested the possible anti-apoptotic and neuroprotective activity of CSP-1103 in a cell-based model of post-ischemic injury, wherein the primary mouse cortical neurons were exposed to oxygen-glucose deprivation (OGD). When added after OGD, CSP-1103 prevented the apoptosis cascade by reducing cytochrome c release and caspase-3 activation and the secondary necrosis. Additionally, CSP-1103 limited earlier activation of p38 and nuclear factor κB (NF-κB) pathways. These results demonstrate that CSP-1103 is neuroprotective in a model of post-ischemic brain injury and provide further mechanistic insights as regards its ability to reduce apoptosis and potential production of pro-inflammatory cytokines. In conclusion, these findings suggest a potential use of CSP-1103 for the treatment of brain ischemia.

Inflammatory Activation of Microglia and Astrocytes in Manganese Neurotoxicity.

Neurotoxicity due to excessive exposure to manganese (Mn) has been described as early as 1837 (Couper, Br Ann Med Pharm Vital Stat Gen Sci 1:41-42, 1837). Extensive research over the past two decades has revealed that Mn-induced neurological injury involves complex pathophysiological signaling mechanisms between neurons and glial cells. Glial cells are an important target of Mn in the brain, both for sequestration of the metal, as well as for activating inflammatory signaling pathways that damage neurons through overproduction of numerous reactive oxygen and nitrogen species and inflammatory cytokines. Understanding how these pathways are regulated in glial cells during Mn exposure is critical to determining the mechanisms underlying permanent neurological dysfunction stemming from excess exposure. The subject of this review will be to delineate mechanisms by which Mn interacts with glial cells to perturb neuronal function, with a particular emphasis on neuroinflammation and neuroinflammatory signaling between distinct populations of glial cells.

DEFICIENCY OF NEURONAL P38A-MAPK ATTENUATES AMYLOID PATHOLOGY AND COGNITIVE DEFICITS IN ALZHEIMER’S MOUSE MODEL

Amyloid β (Aβ) damages neurons and triggers microglial inflammatory activation in the Alzheimer’s disease (AD) brain. Neuroinflammation potentially up-regulates BACE1 expression and increases Aβ production. Recently, we have observed that deletion of p38α-MAPK, a inflammation-responding kinase, in neurons increases the lysosomal degradation of BACE1 protein, thereby reducing in Aβ generation in neuronal cells (Schnöder et al., Journal of Biological Chemistry, Vol. 291, No. 5, pp. 2067–2079, January 29, 2016). We follow this study and delete p38α-MAPK specifically in neurons of Aβ-precursor protein (APP)-transgenic mice with Cre-Lox technique. By using immunohistochemical and biochemical methods, as well as behavior tests, we determined the role of neuronal deletion of p38α-MAPK on Aβ pathology. We can clearly demonstrate that neuronal deficiency of p38α-MAPK significantly decreases cerebral Aβ level, and improves cognitive function in 9-month-old APP-transgenic mice. Thus, our study demonstrates that p38α-MAPK plays a critical role in the regulation of Aβ generation and AD pathogenesis, and suggests that p38α-MAPK might be a novel molecular target for AD therapy.

Estrogens, Neuroinflammation, and Neurodegeneration.

Inflammatory activation of microglia is a hallmark of several disorders of the central nervous system. In addition to protecting the brain against inflammatory insults, microglia are neuroprotective and play a significant role in maintaining neuronal connectivity, but the prolongation of an inflammatory status may limit the beneficial functions of these immune cells. The finding that estrogen receptors are present in monocyte-derived cells and that estrogens prevent and control the inflammatory response raise the question of the role that this sex steroid plays in the manifestation and progression of pathologies that have a clear sex difference in prevalence, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The present review aims to provide a critical review of the current literature on the actions of estrogen in microglia and on the involvement of estrogen receptors in the manifestation of selected neurological disorders. This current understanding highlights a research area that should be expanded to identify appropriate replacement therapies to slow the progression of such diseases.

Deficiency of IκB Kinase β in Myeloid Cells Reduces Severity of Experimental Autoimmune Encephalomyelitis

In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), peripherally developed myelin-reactive T lymphocytes stimulate myeloid cells (ie, microglia and infiltrated macrophages) to trigger an inflammatory reaction in the central nervous system, resulting in demyelination and neurodegeneration. IκB kinase β (IKKβ) is a kinase that modulates transcription of inflammatory genes. To investigate the pathogenic role of IKKβ in MS, we developed strains in which IKKβ was conditionally ablated in myeloid cells and established active or passive EAE in these animals. Deficiency of IKKβ in myeloid cells ameliorated EAE symptoms and suppressed neuroinflammation, as shown by decreased infiltration of T lymphocytes and macrophages and reduced inflammatory gene transcription in the spinal cord at the peak or end stage of EAE. Myeloid deficiency of IKKβ also reduced the transcription of Rorc or Il17 genes in T lymphocytes isolated from lymph nodes, spleen, and spinal cord of EAE mice. Moreover, cultured splenocytes isolated from myeloid IKKβ-deficient EAE mice released less IL-17, interferon-γ, and granulocyte-macrophage colony-stimulating factor after treatment with myelin peptide than splenocytes from IKKβ wild-type EAE mice. Thus, deficiency of myeloid IKKβ attenuates the severity of EAE by inhibiting both the neuroinflammatory activity and the activation of encephalitogenic T lymphocytes. These results suggest IKKβ may be a potential target for MS patients, especially when neuroinflammation is the primary problem.

Age-dependent differences in microglial responses to systemic inflammation are evident as early as middle age.

Whereas age increases microglial inflammatory activities and impairs their ability to effectively regulate their immune response, it is unclear at what age these exaggerated responses begin. We tested the hypotheses that augmented microglial responses to inflammatory challenge are present as early as middle age and that repeated stimulation of primed microglia in vivo would reveal microglial senescence. Microglial gene expression was investigated in a mouse model of repeated systemic inflammation induced by intraperitoneal injection of bacterial lipopolysaccharide (LPS). Following LPS, microglia from middle-aged mice (9-10 mo) displayed larger increases in Tnfα, Il-6, and Il-1β gene expression compared with young adults (2 mo). Similar results were observed in the spleens of middle-aged mice, indicating that exaggeration of both central and peripheral immune responses are already evident at early middle age. Interestingly, despite greater proinflammatory responses to the first LPS challenge in the aged mice, there were no age-dependent differences in either microglia or spleen following a subsequent LPS dose, suggesting that animals at this age retain the ability to effectively control their immune response following repeated challenge. The exacerbated microglial immune response to systemic inflammation at early middle age suggests that the CNS may be vulnerable to age-dependent alterations earlier than previously appreciated.

Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells.

Inflammatory activation of microglia and β amyloid (Aβ) deposition are considered to work both independently and synergistically to contribute to the increased risk of Alzheimer’s disease (AD). Recent studies indicate that long-term use of phenolic compounds provides protection against AD, primarily due to their anti-inflammatory actions. We previously suggested that phenolic compound curcumin ameliorated phagocytosis possibly through its anti-inflammatory effects rather than direct regulation of phagocytic function in electromagnetic field-exposed N9 microglial cells (N9 cells). Here, we explored the prostaglandin-E2 (PGE2)-related signaling pathway that involved in curcumin-mediated phagocytosis in fibrillar β-amyloid peptide (1–42) (fAβ42)-stimulated N9 cells. Treatment with fAβ42 increased phagocytosis of fluorescent-labeled latex beads in N9 cells. This increase was attenuated in a dose-dependent manner by endogenous and exogenous PGE2, as well as a selective EP2 or protein kinase A (PKA) agonist, but not by an EP4 agonist. We also found that an antagonist of EP2, but not EP4, abolished the reduction effect of PGE2 on fAβ42-induced microglial phagocytosis. Additionally, the increased expression of endogenous PGE2, EP2, and cyclic adenosine monophosphate (AMP), and activation of vasodilator-stimulated phosphoprotein, cyclic AMP responsive element-binding protein, and PKA were depressed by curcumin administration. This reduction led to the amelioration of the phagocytic abilities of PGE2-stimulated N9 cells. Taken together, these data suggested that curcumin restored the attenuating effect of PGE2 on fAβ42-induced microglial phagocytosis via a signaling mechanism involving EP2 and PKA. Moreover, due to its immune modulatory effects, curcumin may be a promising pharmacological candidate for neurodegenerative diseases.

Synergy between phenotypic modulation and ROS neutralization in reduction of inflammatory response of hypoxic microglia by using phosphatidylserine and antioxidant containing liposomes

Neuroinflammation caused by microglial activation is a key contributing factor in neurological disorders such as those involving ischaemia. Excess production of reactive oxygen species (ROS) and nitric oxide (NO) stimulates the inflammatory response during ischaemia, significantly damaging cells. Inhibition of inflammatory activation of microglia is a promising potential treatment approach for neurological diseases. In this study, we introduce α-tocopherol and phosphatidylserine (PS) containing liposomes (PST-liposomes) to inhibit the microglial inflammatory response. PS is known to have anti-inflammatory effects on microglia by modulating the microglial phenotype, while α-tocopherol is an antioxidant, known to neutralize ROS. We found that both PS-containing liposomes (PS-liposomes) and PST-liposomes, as compared with phosphatidylcholine containing liposomes, significantly increased viability of hypoxia-treated microglia. The PST-liposomes functioned better than the PS-liposomes and we attribute this superior effect to a synergy between PS and α-tocopherol. This synergic action of PST-liposomes was illustrated in their ability, when incubated with microglia, to reduce NO and pro-inflammatory cytokine (TNF-α) production and increase anti-inflammatory cytokine (TGF-β1) production. Thus, the improved viability of hypoxia-treated microglia when treated with PST-liposomes involved anti-inflammatory effects, including ROS neutralization, as well as induction of a microglial phenotypic change. Our results suggest that PST-liposomes represent a potential therapeutic approach to reducing ischaemic injury in the brain.

Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1

Amyloid β (Aβ) damages neurons and triggers microglial inflammatory activation in the Alzheimer disease (AD) brain. BACE1 is the primary enzyme in Aβ generation. Neuroinflammation potentially up-regulates BACE1 expression and increases Aβ production. In Alzheimer amyloid precursor protein-transgenic mice and SH-SY5Y cell models, we specifically knocked out or knocked down gene expression of mapk14, which encodes p38α MAPK, a kinase sensitive to inflammatory and oxidative stimuli. Using immunological and biochemical methods, we observed that reduction of p38α MAPK expression facilitated the lysosomal degradation of BACE1, decreased BACE1 protein and activity, and subsequently attenuated Aβ generation in the AD mouse brain. Inhibition of p38α MAPK also enhanced autophagy. Blocking autophagy by treating cells with 3-methyladenine or overexpressing dominant-negative ATG5 abolished the deficiency of the p38α MAPK-induced BACE1 protein reduction in cultured cells. Thus, our study demonstrates that p38α MAPK plays a critical role in the regulation of BACE1 degradation and Aβ generation in AD pathogenesis.

The Nogo/Nogo Receptor (NgR) Signal Is Involved in Neuroinflammation through the Regulation of Microglial Inflammatory Activation

Microglia have been proposed to play a pivotal role in the inflammation response of the CNS by expressing a range of proinflammatory enzymes and cytokines under pathological stimulus. Our previous study has confirmed that Nogo receptor (NgR), an axon outgrowth inhibition receptor, is also expressed on microglia and regulates cell adhesion and migration behavior in vitro. In the present study, we further investigated the proinflammatory effects and possible mechanisms of Nogo on microglia in vitro. In this study, Nogo peptide, Nogo-P4, a 25-amino acid core inhibitory peptide sequence of Nogo-66, was used. We found that Nogo-P4 was able to induce the expression of inducible nitric-oxide synthase and cyclooxygenase-2 and the release of proinflammatory cytokines, including IL-1β, TNF-α, NO, and prostaglandin E2 in microglia, which could be reversed by NEP1-40 (Nogo-66(1-40) antagonist peptide), phosphatidylinositol-specificphospholipase C, or NgR siRNA treatment. After Nogo-P4 stimulated microglia, the phosphorylation levels of NF-κB and STAT3 were increased obviously, which further mediated microglia expressing proinflammatory factors induced by Nogo-P4. Taken together, we concluded that Nogo peptide could directly take part in CNS inflammatory process by influencing the expression of proinflammatory factors in microglia, which were related to the NF-κB and STAT3 signal pathways. Besides neurite outgrowth restriction, the Nogo/NgR signal might be involved in multiple processes in various inflammation-associated CNS diseases.

Brain endothelial IL-1R1 mediates central IL-1 induced neuroinflammation and anxiety-like behavior

Interleukin-1 (IL-1) mediates diverse neuropathological effects and behavioral changes in the central nervous system (CNS) through type I IL-1 receptor (IL-1R1). Different CNS cell types are known to mediate different IL-1 effects. In this study, we investigated IL-1 induced neuroinflammation and anxiety using three cell-type specific IL-1R1 expressing mouse lines: Tie2Cre-IL-1R1r/r (IL-1R1 restricted to endothelial cells and hematopoietic cells), LysMCre-IL-1R1r/r (myeloid cells) or HipAAV2Cre-IL-1R1r/r (hippocampal neurons). Following intracerebroventricular (ICV) IL-1 injection microglial activation was induced in all three mouse lines but with distinct morphological characteristics. Microglia in Tie2Cre-IL-1R1r/r mice developed most abundant branches and longest processes length. Cytokine expression analysis showed microglia in wild-type (WT) and Tie2Cre-IL-1R1r/r mice upregulated proinflammatory cytokines IL-1 β and TNF- α , which did not occur in LysMCre-IL-1R1 and AAVCre-IL-1R1 mice which lacked endothelial IL-1R1. We then adoptively transferred SVEC4-10 cells, an IL-1R1 expressing endothelial cell line, into striatum of IL-1R1 knockout mice (IL-1R1r/r). After the transfer, microglial activation was induced by ICV IL-1 but not by saline, indicating endothelial IL-1R1 is sufficient to mediate inflammatory microglial activation. Furthermore, we found endothelial IL-1R1 dependent microglial activation was mediated via exocytosis of danger signals such as ATP. In addition, anxiety-like behavior developed in WT and Tie2Cre-IL-1R1r/r mice but not LysMCre-IL-1R1r/r or AAV2Cre-IL-1R1r/r lines. Collectively, these findings demonstrate that brain endothelial IL-1R1 mediates central IL-1 induced neuroinflammation and anxiety-like behavior.

Continuous vaccinations of 4Aβ1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice

The common pathological hallmark of Alzheimer's disease (AD) is β-amyloid plaques deposition. Immunotherapy is a revolutionary pharmacological treatment for AD, aiming at improving plaque clearance while concomitantly decreasing inflammation. Our previous study prepared antigen 4Aβ1-15 and found that it could alleviate pathologic alterations in APP/PS1 transgenic mice. The objective of our study was to research the changing processes induced by immunotherapy, including the inflammatory factor levels and microglial activation that is closely associated with Aβ burdens clearance. APP/PS1 mice were injected with 4Aβ1-15 6 times. Each time, the inflammatory factors in sera were detected, and a specific fluctuation that first increased and then decreased was found, in which there was a turning point after the third injection. It prompted us to further detect the indicators in the brains after the third injection and the sixth injection. The results showed that the therapeutic effects for Aβ burdens and behaviors were continuously improved during the whole immune processes, whereas the inflammatory factor levels and microglial activation experienced similar specific fluctuations. The novel discovery may provide convenient methods for further detection and evaluation of immunotherapy in disease courses.

Chronic Intermittent Hypoxia Promotes Epigenetic Regulation of Inflammatory Gene Promoters in Microglia

Microglial inflammatory activities contribute to chronic neuroinflammation and cognitive impairments in virtually all CNS disorders. Chronic intermittent hypoxia (CIH), a hallmark of sleep disordered breathing, causes significant hippocampal and cortical neuron loss and subsequent cognitive decline and impaired vigilance. Previously, we demonstrated an upregulation of microglial pro-inflammatory activities early in CIH neuropathology in rodent models. CIH also increased the expression of the Jumonji C family histone demethylase, JMJD3, in microglia in vitro and in vivo. The expression correlated with reduced global histone H3K27 tri-methylation levels, suggesting the potential for increased gene transcription during CIH in immortalized microglia. Therefore, we tested the hypothesis that epigenetic regulation at pro-inflammatory gene promoters contributes to microglial inflammatory activity following early CIH exposure. We used ChIP qPCR to detect JMJD3 binding patterns, in addition to H3K27 tri-methylation patterns, at inflammatory gene promoters in immortalized N9 microglia exposed to 21% O2 (normoxia) or 10 min cycles of 21% O2 and 1% O2 (CIH). Preliminary results demonstrate that CIH increases JMJD3 binding at the inflammatory genes interleukin-6 and cyclooxygenase-2 compared to normoxia. We further show high H3K27 trimethylation at inflammatory genes in normoxic samples, consistent with minimal inflammatory gene transcription in the healthy CNS. These studies are the first to investigate the effects of histone modifying enzymes during CIH in any cell type, and to suggest a mechanistic underpinning for CIH-induced neuroinflammation. Supported by NIH R01HL111598.

Methionine sulfoxide reductase A negatively controls microglia-mediated neuroinflammation via inhibiting ROS/MAPKs/NF-κB signaling pathways through a catalytic antioxidant function.

Oxidative burst is one of the earliest biochemical events in the inflammatory activation of microglia. Here, we investigated the potential role of methionine sulfoxide reductase A (MsrA), a key antioxidant enzyme, in the control of microglia-mediated neuroinflammation. MsrA was detected in rat microglia and its expression was upregulated on microglial activation. Silencing of MsrA exacerbated lipopolysaccharide (LPS)-induced activation of microglia and the production of inflammatory markers, indicating that MsrA may function as an endogenous protective mechanism for limiting uncontrolled neuroinflammation. Application of exogenous MsrA by transducing Tat-rMsrA fusion protein into microglia attenuated LPS-induced neuroinflammatory events, which was indicated by an increased Iba1 (a specific microglial marker) expression and the secretion of pro-inflammatory cytokines, and this attenuation was accompanied by inhibiting multiple signaling pathways such as p38 and ERK mitogen-activated protein kinases (MAPKs) and nuclear factor kappaB (NF-κB). These effects were due to MsrA-mediated reactive oxygen species (ROS) elimination, which may be derived from a catalytic effect of MsrA on the reaction of methionine with ROS. Furthermore, the transduction of Tat-rMsrA fusion protein suppressed the activation of microglia and the expression of pro-inflammatory factors in a rat model of neuroinflammation in vivo. This study provides the first direct evidence for the biological significance of MsrA in microglia-mediated neuroinflammation. Our data provide a profound insight into the role of endogenous antioxidative defense systems such as MsrA in the control of microglial function.

Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease.

Alzheimer's disease (AD) is a neurodegenerative disease characterized by extracellular deposits of amyloid β peptide (Aβ) and microglia-dominated neuroinflammation. The therapeutic options for AD are currently limited. In this study, we investigated the antiinflammatory effects and the underlying molecular mechanisms of Ginkgo biloba extract EGb 761 when administered to TgCRND8 AD mice, which overexpress human Alzheimer's amyloid precursor protein (APP) specifically in neurons. We gave APP-transgenic mice EGb 761 as a dietary supplement for 2 or 5months. Plasma concentrations of EGb 761 components in mice were in the same range as such concentrations in humans taking EGb 761 at the recommended dose (240mg daily). Treatment with EGb 761 for 5months significantly improved the cognitive function of the mice as measured by the Barnes Maze test. It also attenuated the loss of synaptic structure proteins, such as PSD-95, Munc18-1, and SNAP25. Treatment with EGb 761 for 5months inhibited microglial inflammatory activation in the brain. The effects of treatment with EGb 761 for 2months were weak and not statistically significant. Moreover, EGb 761 activated autophagy in microglia. Treatment with EGb 761 decreased Aβ-induced microglial secretion of TNF-α and IL-1β and activation of caspase-1, both of which were abolished by the inhibition of autophagy. Treatment with EGb 761 also reduced the concentrations of NLRP3 protein that colocalized with LC3-positive autophagosomes or autolysosomes in microglia. Additionally, long-term treatment with EGb 761 may reduce cerebral Aβ pathology by inhibiting β-secretase activity and Aβ aggregation. Therefore, long-term treatment with G. biloba extract EGb 761, a clinically available and well-tolerated herbal medication, ameliorates AD pathology by antiinflammatory and Aβ-directed mechanisms.